Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

ACCP 2017

ACCP 2017 Poster of a Phase 1 Ethnic PK Study

This poster was presented at the 2017 American College of Clinical Pharmacology (Sept 17–19, 2017) in San Diego, California. It presents the results of a Phase I study evaluating the pharmacokinetics of rivoceranib (apatinib) in healthy Caucasian, Japanese, and Chinese subjects. The results from this study indicated that there were no statistically significant differences in key pharmacokinetic parameters between the study groups. To read the full study report download the poster.